Pro Familia Altera Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Pro Familia Altera is evaluating new treatments aimed at reducing risk and improving outcomes for patients with cardiovascular disease and related conditions such as hypertension and heart failure.
- High cardiovascular risk
- Heart failure with preserved ejection fraction
- Hypercholesterolemia
- Hypertension
- Established cardiovascular disease
These studies support the clinic’s commitment to advancing heart health in the Katowice region.
Immune System Diseases
Research at the center includes trials that test innovative therapies for immune system diseases like atopic dermatitis and psoriasis.
- Atopic dermatitis
- Plaque psoriasis
- Palmoplantar pustulosis
- Prurigo nodularis
- Vitiligo
The goal is to improve skin symptoms and quality of life for affected individuals.
Musculoskeletal Diseases
The site conducts investigations targeting chronic pain conditions within the musculoskeletal domain.
- Chronic non‑specific low back pain
- Chronic pain due to diabetic peripheral neuropathy
- Musculoskeletal pain management
Findings aim to offer safer, non‑opioid options for patients suffering persistent discomfort.
Nervous System Diseases
Trials focus on disorders of the nervous system, particularly diabetic peripheral neuropathy.
- Diabetic peripheral neuropathy
- Neuropathic pain
- Chronic neuropathic pain
Researchers seek therapies that alleviate nerve‑related pain and improve functional ability.
Nutritional and Metabolic Diseases
Studies address metabolic challenges by testing agents for type 2 diabetes and related metabolic disorders.
- Type 2 diabetes mellitus
- Hyperuricemia associated with gout
- Chronic kidney disease
- Obesity
- Metabolic syndrome
The work aligns with the clinic’s effort to reduce complications of metabolic disease.
Respiratory Tract Diseases
The clinic’s respiratory program evaluates novel inhaled treatments for chronic obstructive pulmonary disease and severe asthma.
- COPD
- Severe asthma
- Moderate to very severe COPD
- Respiratory syncytial virus infection
- Bronchitis
These trials aim to lower exacerbation rates and improve lung function for patients.
Skin and Connective Tissue Diseases
Investigations target a range of skin and connective tissue diseases, testing biologics and small molecules.
- Atopic dermatitis
- Plaque psoriasis
- Palmoplantar pustulosis
- Prurigo nodularis
- Vitiligo
Outcomes include reduced itching, lesion clearance, and better skin health.
Virus Diseases
A focused study examines immune responses to a vaccine against respiratory syncytial virus in older adults.
- RSV vaccine revaccination
- Immune response monitoring
- Safety assessment of RSV vaccine
The research supports preventive strategies for viral respiratory illness.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 42 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1AstraZeneca AB5active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB9trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pro Familia Altera Sp. z o.o.
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 42 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 3 | Unknown | 2021-04-29 | 2024-07-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.